Cecilia Yshii Tamashiro, MD
Pulmonary Disease · Springfield, MONPI 1750518080
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,941 of the $4,891 with a category attached, or 60.1%. Intuitive Surgical accounts for 78.1% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $1,924, 5.5 times the $349 reported in 2019.
Across 82 payments — averaging $59.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- AstraZeneca$202
- Boehringer Ingelheim$120
- GSK$94
- Grifols USA, LLC$61
- Avadel CNS Pharmaceuticals, LLC$54
- plus $542 from 20 others
What the payments were for
- Travel & lodging$2,94160%
- Food & beverage$1,90039%
- Education$501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 20 | $3,819 |
| AstraZeneca | 14 | $202 |
| Boehringer Ingelheim | 7 | $120 |
| GSK | 5 | $94 |
| Grifols USA, LLC | 3 | $61 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $54 |
| Mylan Specialty L.p. | 4 | $53 |
| Amgen | 3 | $49 |
| United Therapeutics Corporation | 2 | $41 |
| Novartis | 3 | $40 |
| ANI Pharmaceuticals, Inc. | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 2 | $36 |
| Philips North America LLC | 2 | $34 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| AbbVie | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| ZOLL Respicardia, Inc. | 1 | $20 |
| CSL Behring | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Electromed, Inc. | 1 | $17 |
| Baxter Healthcare | 1 | $17 |
| Siemens Medical Solutions USA, Inc. | 1 | $17 |
| Merck | 1 | $14 |
| Pulmonx Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,421
How this compares
$4,891 in reported general payments places this provider in the 65th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 16 | $217,880 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 75 | $57,211 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $49,301 |
| Spiriva RespimatTiotropium Bromide | 32 | $18,843 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $11,744 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $11,248 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $7,563 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $7,357 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $3,808 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 104 | $2,368 |
| BreynaBudesonide/Formoterol Fumarate | 13 | $1,513 |
| Azelastine Hcl | 25 | $473 |
| Fluticasone Propionate | 33 | $392 |
| Montelukast Sodium | 46 | $382 |
| Azithromycin | 24 | $348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat | $120 | $236,72448 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $202 | $68,955119 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $94 | $68,113117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Springfield
- Mitchell AhrensSpringfield$12K
- Amy Ford TurnerSpringfield$12K
- Humam FarahHannibal$840K
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Munaf SiyamwalaIndependence$413K
- Edward CharbekSaint Louis$372K
- Adeel KhanWashington$316K
- Marin KollefSaint Louis$264K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.